McCann Healthcare names four as co-CEOs

Share this article:
McCann Healthcare names four as co-CEOs
McCann Healthcare names four as co-CEOs
McCann Healthcare Worldwide announced a new “Office of the CEO” under which four executives will share leadership responsibility.

The realignment follows the December departure of McCann Healthcare chief Richard Nordstrom, who had held that post since 2005.

The four execs, who will take on responsibility for leading the network in addition to leading their units, are: Marci Piasecki, CEO of Torre Lazur Healthcare Group; Maureen Regan, managing partner of RCW Group; David Backmann, DCFO of McCann Healthcare Worldwide; and John Cahill, president, McCann Healthcare EMEA and Asia Pacific as well as head of med ed.

Cahill, who is based in London, will be first among equals, serving as chairman of the Office of the CEO, with oversight for global operations as well as multinational coordination on behalf of clients, the company said, and will serve as “the single point of contact for the McCann Healthcare Worldwide Network,” though different companies will have different point persons among the four.

McCann Worldgroup chief John Dooner said in a statement: The new structure both recognizes the leadership achievements of the four executives and will help us meet our clients' global needs by fostering increased collaboration between McCann's healthcare companies around the world. We thank Richard for all that he has accomplished and wish him well with his new plans.”

The changes were first reported in the January issue of MM&M.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.